The influence of chirality, physicochemical properties, and permeation enhancers on the transdermal permeation of amlodipine across rat skin

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 724-734

  Zeng, Aiguo ^a   Wang, Changhe ^b   Yuan, Bingxiang ^a   Yang, Guangde ^a   Fu, Qiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Institute for Drug Control   (China)

Author keywords

Amlodipine; Chirality; Ethanol; Physicochemical properties; Skin permeation; Terpene

Indexed keywords

ALCOHOL; AMLODIPINE; LIMONENE; MENTHOL; TERPENE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CHIRALITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; ENTHALPY; EPIDERMIS; FEMALE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MELTING POINT; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; RACEMIC MIXTURE; RAT; SKIN PENETRATION; STEADY STATE; THERMODYNAMICS;

ADMINISTRATION, CUTANEOUS; AMLODIPINE; ANIMALS; DRUG SYNERGISM; FEMALE; PERMEABILITY; PHYSICOCHEMICAL PHENOMENA; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SKIN ABSORPTION; STEREOISOMERISM;

EID: 77952505231     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903460438     Document Type: Article

References (37)

1. Drayer DE. (1986). Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin Pharmacol Ther, 40:125-33.
2. Islam MR, Mahdi JG, Bowen ID. (1997). Pharmacological importance of stereochemical resolution of enantiomeric drugs. Drug Saf, 17:149-65.
3. Midha KK, Mckay G, Rawson MJ, Hubbard JW. (1998). The impact of stereoisomerism in bioequivalence studies. J Pharm Sci, 87:797-802.
4. Mikus P, Marakova K, Marak J, Nemec I, Valaskova I, Havranek E. (2008). Direct quantitative determination of amlodipine enantiomers in urine samples for pharmacokinetic study using on-line coupled isotachophoresis-capillary zone electrophoresis separation method with diode array detection. J Chromatogr B Analyt Technol Biomed Life Sci, 875:266-72.
5. Wainer I. (1993). Drug stereochemistry: Analytical methods and pharmacology. New York: Marcel Dekker.
6. Reddy IK, Mehvar R. (2004). Chirality in drug design and development. New York: Marcel Dekker.
7. Rustichelli C, Gamberini MC, Ferioli V, Gamberini G. (1999). Properties of the racemic species of verapamil hydrochloride and gallopamil hydrochloride. Int J Pharm, 178:111-20.
8. Kommuru TR, Khan MA, Reddy IK. (1998). Racemate and enantiomers of ketoprofen: Phase diagram, thermodynamic studies, skin permeability, and use of chiral permeation enhancers. J Pharm Sci, 87:833-40.
9. Heard CM, Brain KR. (1995). Does solute stereochemistry influence percutaneous penetration? Chirality, 7:305-9.
10. Miyazaki K, Kaiho F, Inagaki A, Dohi M, Hazemoto N, Haga M, et al. (1992). Enantiomeric difference in percutaneous penetration of propranolol through rat excised skin. Chem Pharm Bull, 40:1075-6.
11. Benezra C, Stampf JL, Barbier P, Ducombs G. (1985). Enantiospecificity in allergic contact dermatitis. Contact Derm, 13:110-4.
12. Ahmed S, Imai T, Yoshigae Y, Otagiri M. (1997). Stereospecific activity and nature of metabolizing esterases for propranolol prodrug in hairless mouse skin, liver and plasma. Life Sci, 61:1879-87.
13. Udata C, Tirucherai G, Mitra AK. (1999). Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs. J Pharm Sci, 88:544-50.
14. Kommuru TR, Khan MA, Reddy IK. (1999). Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. Chirality, 11:536-40.
15. Heard CM, Suedee R. (1996). Stereoselective adsorption and trans-membrane transfer of propranolol enantiomers using cellulose derivatives. Int J Pharm, 139:15-23.
16. Touitou E, Chow DD, Lawter JR. (1994). Chiral [beta]-blockers for transdermal delivery. Int J Pharm, 104:19-28.
17. Roy SD, Chatterjee DJ, Manoukian E, Divor A. (1995). Permeability of pure enantiomers of keterolac through human cadaver skin. J Pharm Sci, 8:987-90.
18. Murdoch D, Heel RC. (1991). Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs, 41:478-505.
19. Meredith PA, Elliott HL. (1992). Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet, 22:22-31.
20. Helms SR. (2007). Treatment of feline hypertension with transdermal amlodipine: A pilot study. J Am Anim Hosp Assoc, 43:149-56.
21. Goldmann S, Stoltefuss J, Born L. (1992). Determination of the absolute configuration of the active amlodipine enantiomer as (-) -S: A correction. J Med Chem, 35:3341-4.
22. Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, Gardiner DG, et al. (1986). Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem, 29:1696-702.
23. Kumar D, Aqil M, Rizwan M, Sultana Y, Ali M. (2009). Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine. Pharmazie, 64:80-5.
24. McDaid DM, Deasy PB. (1996). Formulation development of a transdermal drug delivery system for amlodipine base. Int J Pharm, 133:71-83.
25. Luka J, Josi D, Kremser M, Kopitar Z, Milutinovi S. (1997). Pharmacokinetic behaviour of R- (+) - and S- (-) -amlodipine after single enantiomer administration. J Chromatogr B Analyt Technol Biomed Life Sci, 703:185-93.
26. Streel B, Laine C, Zimmer C, Sibenaler R, Ceccato A. (2002). Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J Biochem Biophys Methods, 54:357-68.
27. El-Kattan AF, Asbill CS, Kim N, Michniak BB. (2001). The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int J Pharm, 215:229-40.
28. Duddu SP, Grant DJ. (1992). Formation of the racemic compound of ephedrine base from a physical mixture of its enantiomers in the solid, liquid, solution, or vapor state. Pharm Res, 9:1083-91.
29. Jacques J, Collet A, Wilen SH. (1981). Enantiomers, racemates, and resolutions. New York: Wiley.
30. Manabe E, Sugibayashi K, Morimoto Y. (1996). Analysis of skin penetration enhancing effect of drugs by ethanol-water mixed systems with hydrodynamic pore theory. Int J Pharm, 129:211-21.
31. Hatanaka T, Inuma M, Sugibayashi K, Morimoto Y. (1990). Prediction of skin permeability of drugs. I. Comparison with artificial membrane. Chem Pharm Bull, 38:3452-9.
32. Higuchi WI, Liu P, Ghanem AH, Song W. (1987). Mechanism of ethanol effect on the simultaneous transport and metabolism of β-estradiol in hairless mouse skin. Control Release Bioact Mater, 14:101-2.
33. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. (1990). Percutaneous absorption enhancement of an ionic molecule by ethanol-water systems in human skin. Pharm Res, 7:762-6.
34. Arellano A, Santoyo S, Martin C, Ygartua P. (1996). Enhancing effect of terpenes on the in vitro percutaneous absorption of diclofenac sodium. Int J Pharm, 130:141-5.
35. Sinha VR, Kaur MP. (2000). Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm, 26:1131-40.
36. Cornwell PA, Barry BW, Stoddart CP, Bouwstra JA. (1994). Wide-angle X-ray diffraction of human stratum corneum: Effects of hydration and terpene enhancer treatment. J Pharm Pharmacol, 46:938-50.
37. Williams AC, Barry BW. (1991). Terpenes and the lipid-proteinpartitioning theory of skin penetration enhancement. Pharm Res, 8:17-24.